Captor Therapeutics ® Investor Relations

      Investor Relations

      Notice of convocation of the Ordinary General Shareholders Meeting and draft resolutions of the Ordinary General Shareholders Meeting

      Publication date: 2022-06-03
      Number: RB ESPI 20/2022

      Current Report No. 20/2022

      Date of preparation: June 3, 2022.

      Subject: Notice of convocation of the Ordinary General Shareholders Meeting and draft resolutions of the Ordinary General Shareholders Meeting

      Legal basis: Article 56 Section 1 Item 2 of the Act on Public Offering - current and periodic information

      The Management Board of Captor Therapeutics S.A. with its registered office in Wrocław (the “Company”), acting pursuant to Article 399 § 1 in connection with Article 402¹ and 402² of the Commercial Companies Code, informs that the Ordinary General Shareholders Meeting of the Company was convened for 30 June 2022 at 2:00 pm and will be held in Wrocław, at ul. Duńska 9 (54-427 Wrocław), in the DELTA building.

      The Management Board of the Company submits the following in the attachment to this report:

      1. the full text of the announcement together with the agenda of the Ordinary General Meeting of Shareholders (Attachment No. 1),
      2. draft resolutions to be discussed at the Ordinary General Meeting of the Company (Attachment No 2);
      3. the text of the Supervisory Board's resolution giving a positive opinion on the draft resolutions to be adopted by the Ordinary General Meeting of Shareholders of the Company (Attachment No 3);
      4. opinion of the Company's Management Board on the amendment to authorize the Company's Management Board to increase the Company's share capital within the limits of the authorized capital with the option to exclude pre-emptive rights of the existing shareholders in full and to amend the Company's Articles of Association in connection with the Company's authorized capital (amendment to Resolution No. 25 of the Ordinary General Meeting of Shareholders of 26 June 2020, as amended, on authorizing the Company's Management Board to increase the Company's share capital within the limits of the authorized capital with the option to exclude pre-emptive rights of the existing shareholders and to amend the Company's Articles of Association in connection with the Company's authorized capital) (Appendix no. 4);
      5. the report on remuneration prepared by the Company's Supervisory Board for 2021 (attachment no. 5);
      6. the report of the independent auditor on the performance of an assurance service providing reasonable assurance regarding the assessment of the remuneration report of Captor Therapeutics S.A. for the year 2021 (Annex no. 6);
      7. the report of the Supervisory Board of the Company for 2021 (attachment no. 7).

      Attachments: